Cost of new medications could bankrupt health care | Don Brunell

The good news is we are developing new life-saving medications every day. The bad news is they are very expensive and paying for them could bankrupt our health care system.

The good news is we are developing new life-saving medications every day. The bad news is they are very expensive and paying for them could bankrupt our health care system.

For example, Avastin, which is prescribed to treat a number of cancers, costs $100,000 a year per patient. Soliris, used to treat a rare blood and kidney disorder, costs almost $410,000 per year.

The latest medication drawing attention is Sovaldi. While highly effective in curing patients with chronic hepatitis C, it costs about $1,000 a pill or about $84,000 for a standard 12-week treatment.

Chronic hepatitis C affects 3.2 million people in the United States and about 150 million worldwide. It is a devastating virus that can be deadly if not treated effectively.  It is a blood-borne virus that causes inflammation of the liver which, if left untreated, can lead to permanent liver damage.

While it can be contracted through accidental needle sticks or long term kidney dialysis, people most at risk are IV drug users or people who use unlicensed, unclean tattoo, body piercing or acupuncture practitioners.  Most troubling, pregnant women with the disease can pass it on to their unborn babies.

Accurate statistics are difficult to come by because the virus can lie dormant for decades and experts estimate barely half of those infected have been tested.

Adding to the problem is the fact that many of those infected are unable to pay for their medical care. The Annals of Internal Medicine reports, “Our study and others have found that persons with chronic hepatitis C virus infection are frequently poor and less educated . . . .”And therein lies the dilemma.

There is no question that Sovaldi is a breakthrough drug.  It can cure patients within 12 to 24 weeks where other treatments can take up to a year. The cure rate for Sovaldi is up to 90 percent while other treatments are only about 50 percent. But its high price is driving up health care costs.Recently, Anthem Blue Cross and Blue Shield officials cited costly new hepatitis C drugs as one reason for a 12.5 percent premium increase.  And Congress, fearful of the impact on Medicaid and Medicare costs, has asked Gilead, which owns Sovaldi, to explain its pricing.We should care because we’re paying the bill.

Since Obamacare took effect in October, an estimated 7.2 million people have enrolled in its expanded Medicaid program and the Children’s Health Insurance Program, swelling the ranks to 66 million people, according to the U.S. Department of Health and Human Services. Taxpayers are responsible for subsidizing the medical care for those 66 million people.

Elected officials need to be careful here. The government can severely restrict access to high-cost drugs for Medicaid patients, increase taxes to cover the cost or try to impose price controls on drug companies.

The most politically expedient option might seem to be price controls.  But drug companies spend billions to develop these miracle drugs. The Congressional Budget Office reported in 2006 that drug companies spent on average more than $800 million to develop an innovative new drug, including the cost of failed projects and the value of forgone alternative investments.

The question is will they continue to take those risks if the government imposes price controls?

Finally, with the current focus on wellness and disease prevention, it is essential that we remind people that bad choices have bad consequences. If people understand that their bad choices lead to higher taxes and higher insurance premiums, perhaps we can put a dent in the rising cost of health care.Until that happens, we are facing some very difficult choices and there are no easy answers.


More in Business

Enumclaw’s QFC debuts home delivery service

The first order is free, but other orders will come with a charge.

Boeing’s venture into hypersonic jets | Don Brunell

The company’s come a long way since nearly crashing the company with its first attempt at supersonic flight.

Avoiding trouble while Tweeting | Don Brunell

Your social media can hurt you or help you when looking for a job.

Columbia River treaty talks too vital to ignore | Don Brunell

The United States and China are currently renegotiating the Columbia River Treaty.

Bellevue company patent infringement win gives small investors hope | Don Brunell

Until recently, our courts have been little help to patent owners.

Podiatrist opens Enumclaw practice

Go see Dr. Bock at 853 Watson Street North, Suite 100.

American giving has surpassed $400 billion | Don Brunell

“Americans’ record-breaking charitable giving in 2017 demonstrates that even in divisive times our commitment to philanthropy is solid.”

Cementing radioactive wastes could save billions | Don Brunell

According to a recent article in the Tri-Cities Herald, the first phase of the demonstration project, grouting three gallons of waste held in Hanford’s underground tanks was successfully completed last December.

Mining contaminated waters to increase copper supplies | Don Brunell

With worldwide demand for copper soaring and there is new pressure to open new mines, expand existing ones, and add ore processing capacity — all of which have serious associated environmental challenges.

GE’s tumble from grace | Don Brunell

General Electric, once the world’s most valuable company, has been topped by Walgreens.

Vintage items, gifts and more at new Enumclaw shop

Featuring an eclectic mix of merchandise, partners Tori Ammons and Melissa Oglesbee… Continue reading

Jetsons cartoon robots now reality | Don Brunell

In April, the U.S. Labor Dept. reported a record high 844,000 unfilled positions in the hospitality industry — which is one out of eight jobs available today.